---
document_datetime: 2023-09-21 19:04:36
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/paglitaz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: paglitaz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3420108
conversion_datetime: 2025-12-27 13:08:39.565984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Paglitaz

Procedural steps taken and scientific information after the authorisation

<!-- image -->

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0002              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal | 15/01/2014 product                  |                                                | SmPC, Labelling and PL           |           |
| IB/0001              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                         | 14/11/2013                          |                                                | SmPC, Annex II, Labelling        |           |

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | and PL   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|

Medicinal product no longer authorised